GSK Targets £1.9B in Annual Savings by 2029 to Boost Drug Pipeline
GSK announced a cost-reduction program on Tuesday aiming for £1.9 billion in annual savings by 2029. The savings will be redirected to expand its late-stage drug pipeline and offset revenue losses from an impending patent expiration on a key HIV treatment. The initiative is part of GSK's strategy to strengthen its pharmaceutical portfolio amid competitive pressures.
Key facts
- GSK announced a cost-reduction initiative on Tuesday.
- Target is £1.9 billion in annual savings by 2029.
- Savings will be channeled toward late-stage pipeline expansion.
- The program cushions against a patent cliff on a leading HIV treatment.
- The HIV treatment is one of GSK's leading products.
Entities
Institutions
- GSK
Sources
- Quartz —